The clinical potential and challenges of sequencing cancer genomes for personalized medical genomics
Related Experiment Video
Updated: Jun 7, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Nicole Cloonan1, Nic Waddell, Sean M Grimmond
1The University of Queensland, Queensland Centre for Medical Genomics, Institute for Molecular Bioscience, 306 Carmody Road, St Lucia, QLD 4072, Australia. n.cloonan@uq.edu.au
Abstract:
Next-generation sequencing is revolutionizing the way in which genomic-scale biological research is performed, and its effects are beginning to be translated medically. Large-scale international collaborations for the comprehensive sequencing of the genome, epigenome, and transcriptomes of cancers and corresponding 'normal' (germ-line) DNA are heralding the start of personalized medical genomics. The promise of eliminating conjecture when determining treatment approaches is certainly appealing for both patients and clinicians; however, several major issues must be resolved before next-generation sequencing will be adopted as a routine clinical tool for patients. This feature review explores the clinical potential and challenges of studying cancer genomes for personalized medical genomics.
Related Concept Videos
Genomics
Next-generation Sequencing
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features.
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
Sanger Sequencing
Pharmacogenetics and Pharmacogenomics: Overview

